丙戊酸（VPA）抗體

產(chǎn)品簡(jiǎn)介：

鼠抗丙戊酸單抗，Mouse anti valproic acid Antibody

Valproic acid (VPA) was initially synthesized in 1882 by Burton as a derivative of valeric acid, which is a branched, short-chain, and naturally occurring fatty acid present in both plants and animals. However, the anticonvulsant properties of VPA were discovered by Eymard in 1962 while attempting to synthesize new compounds from VPA.

其它名稱：丙戊酸單抗，鼠抗VPA抗體,valproic acid Antibody

貨號(hào)：grVA101

應(yīng)用：POCT，LITIA

特異性：valproic acid

來(lái)源：Mouse

存貯：-20℃

產(chǎn)品說(shuō)明：

Valproic acid was initially discovered in 1882 and was used as an inert solvent until 1962, when its antiepileptic properties were discovered by means of the Khellin derivative trial.In 1966 it was trialed as a mood stabilizer with great success and was eventually approved by the FDA in 1994 when it was compared to lithium for the treatment of bipolar disorder.

Valproic acid’s main antiepileptic mechanism of action is T-calcium channel blockade, as well as some mild sodium channel blockade. Lastly, valproic acid also blocks histone deacetylase 1 which prevents the acetylation of genes associated with inflammatory transcription. Valproic acid is considered a first line treatment for bipolar disorder and acute mania and is comparable to lithium.Valproic acid has also been used off label to address impulsivity and agitation post traumatic brain injury.

Valproic acid (VPA) ia as a highly prevalent medication with multifaceted therapeutic applications in various neurological and psychiatric disorders. The therapeutic uses of VPA include epilepsy treatment across different seizure types, bipolar disorder management, and migraine prophylaxis. The mechanism of action for VPA involves the enhancement of inhibitory neurotransmission and the modulation of voltage-gated ion channels.

產(chǎn)品注意事項(xiàng)：

1.本品為蛋白質(zhì)制劑，未添加任何防腐劑和保護(hù)劑，在2-8℃可以短暫保存。

2.本品僅作為診斷試劑原輔材料，不得用于診斷或治療。